Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 16 2023 - 4:08PM
OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on
patients treated by ear, nose and throat (ENT) and allergy
specialists, today announced that the company has granted a
non-qualified stock option award to purchase 100,000 shares of its
common stock to a new employee as an inducement material for
accepting employment with OptiNose. The stock option award was
granted outside of the OptiNose, Inc. 2010 Stock Incentive Plan in
accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option award was granted on the new
employee’s hire date June 16, 2023 with an exercise price of $1.16
which is equal to the closing price of the company’s common stock
as reported by Nasdaq on the grant date.
The stock option award has a 10-year term and
vests over four years, with one-fourth of the stock options subject
to the award vesting on the first anniversary of the grant date and
the remainder vesting in thirty-six equal monthly installments
thereafter. Vesting of the stock options is subject to continued
service with the company through the applicable vesting date.
About OptinoseOptinose is a
specialty pharmaceutical company focused on serving the needs of
patients cared for by ear, nose and throat (ENT) and allergy
specialists. To learn more, please visit www.optinose.com or
follow us on Twitter and LinkedIn.
Optinose Investor
ContactJonathan
Neelyjonathan.neely@optinose.com267.521.0531
OptiNose (NASDAQ:OPTN)
Historical Stock Chart
From Apr 2024 to May 2024
OptiNose (NASDAQ:OPTN)
Historical Stock Chart
From May 2023 to May 2024